[89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial

INTRODUCTION: Immune-mediated interstitial pneumonitis may be treated with anti-CD20 therapy after failure of conventional therapies. However, clinical response is variable. It was hypothesized that autoreactive CD20-positive cells may play an important role in this variability. This prospective stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Adams, H., van de Garde, E. M. W., Vugts, D. J., Grutters, J. C., Oyen, Wim. J.G., Keijsers, R. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199842/
https://www.ncbi.nlm.nih.gov/pubmed/36826476
http://dx.doi.org/10.1007/s00259-023-06143-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199842/
https://www.ncbi.nlm.nih.gov/pubmed/36826476
http://dx.doi.org/10.1007/s00259-023-06143-1

Ejemplares similares